Thrilled to see this out. Untethered nSpCas9 and MMLV-RT efficiently install edits in human cells. Great The Joung Lab team work led by the fantastic Julian Grünewald.

Can't wait to boost the lab with the generous support provided by the Aventis Foundation. Please reach out, if you're interested in engineering #CRISPR technologies for application in cardiovascular disease! #newPI 🚀

Today in Frontiers - Medicine⁩ Sarah Dehne ⁦Carlo Riede⁩ ⁦@rosa_klotz⁩ ⁦⁦Mohammad Golriz⁩ et al: recombinant #coagulation factors are associated with thrombotic complications and mortality in #LTx. Now an RCT is needed! ⁦Anästhesiologie UKHD⁩ frontiersin.org/articles/10.33…

Enlightening Results 💡 🙏🏽Thank you for the kind words! Patient’s are integral team members toward overall treatment plan. We fully believe it’s #Teamwork that helps to empower all parties involved in caring for a patient, including THE PATIENT. Hopefully the tides continue this path. #TumorBoardTuesday

Check out our multivalent CAR T cell study in Neuro-Oncology Advances Editor - Neuro-Oncology Advances. TanCART eliminated even heterogeneous brain tumors in preclinical models. Congrats to lead author @schmidtsandrea & thanks to all collaborators MGH Neurosurgery MassGeneralNeuroscience academic.oup.com/noa/advance-ar…

1. ENTER #mRNAvaccines for #pancreaticcancer! Long-term #PDAC survivor story PART3. "Do #PDACs REALLY have vaccine neoantigens (NAs)"? (aren’t they lowly mutated?) If each patient = own NAs, how do you vaccinate? Maybe mRNA? But how? nature nature.com/articles/s4158… 👇🏽 [1/32]

Excited to highlight Nature Biomedical Engineering cover story on PERC, peptide-based delivery of #CRISPR RNPs into T cells for ex vivo gene editing with reduced toxicity vs. electroporation. Great work from dana foss et al. Ross Wilson Justin Eyquem @MarsonLab #CARTcell rdcu.be/dcw3w

How mRNA could help fight deadly cancer - a DW News feature on #mRNA technology as a potential treatment for pancreatic #cancer with Niels Halama updates. youtu.be/ExfMY30EoD4

ℹ️ Darmkrebsstudie am #UKHD mit 4,6 Mio. Euro gefördert. Aktuell gestartete „SELREC-Studie“ ist Projekt der Initiative Nationale Dekade gegen Krebs des By Ethical Hacker / Beteiligung von rund 35 Zentren in ganz Deutschland. Mehr dazu: klinikum.uni-heidelberg.de/newsroom/darmk…

Anxiolytics cause anxiety in #PancreaticCancer cell.com/trends/cancer/… By Yang Chen (huge thanks for the heavy lift here!) in Trends in Cancer A commentary on @mike_feigin Abby Cornwell recent paper in Clinical Cancer Research aacrjournals.org/clincancerres/…

First approval for a #CRISPR therapy in the world. UK MHRA has authorized Exagamglogene autotemcel (Casgevy) this morning. What a historic and uplifting day for patients and for the gene & cell therapy field. gov.uk/government/new…

Wir suchen eine/n motivierte/n WeiterbildungsassistentIn für die Zusatzweiterbildung Infektiologie ab 1. Maerz Mind. Vorerfahrung 2 Jahre Innere Medizin. Wir freuen uns auf Ihre Bewerbung! Und bitte weiter teilen!!! karriere.klinikum.uni-heidelberg.de/index.php?ac=j…

The moving boxes are ready and waiting: Welcome to Prof Dr. Niels Halama and team - our new research division. They will work on integrating broad aspects of immunological parameters for the successful development and optimization of therapeutic approaches in clinical translation

Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer NEJM Evidence doi.org/10.1056/EVIDoa… 🔎Phs-2 SEQUENCE trial, 157 pts 👉mPFS: 7.9 vs 5.2 mo 👉 mOS: 13.2 vs 9.7 mo 🧐Therapeutic sequencing gains momentum in #PDAC, see also ALPACA @GI24 ESMO - Eur. Oncology

Robotic 🤜🤛 open pancreatoduodenectomy : the EUROPA RCT 🇩🇪 🥇 Primary endpoint CCI no difference 🟰 90 days mortality 4.8 % 🟰 blood loss 🤖 Higher pancreas specific complications (60% vs. 30%) and DGE 🙅‍♂️ Intraop conversion rate 23% 🫵 Comments?! thelancet.com/pdfs/journals/…

1st RCT #robot vs #open #pancreatoduodenectomy is out: phase 2 #EUROPA trial The Lancet Reg Health-Europe ! Will be published with our invited comment Nine de Graaf 🔑 No benefits robot 🔑 Conclusion? Done early in the centers’ learning curve ➡️ 23% conversion rate 🔑 Phase 3 RCTs needed:

Brutal. Needs to be banned.

🔵⚪️ Mason Greenwood makes it two in 30 minutes, excellent debut as Olympique Marseille new player.

Cancer escapes immunotherapies by mutating its surface. This means even groundbreaking #CARTCell therapies fail too often because of cancer resistance. But what if we could use #GenerativeAI to design CAR-T with de novo binders faster and smarter, targeting even resistant tumors?

Very excited about the first preprint from our lab TU München! This is a fun gene & cell therapy collaboration led by Andrea Schmidts's Lab. We use generative #AI to design new #CARTcell therapies. Check out Andrea's thread & thanks to the whole team! biorxiv.org/content/10.110…